NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding
NovoCure revenue outlook rises after a Q2 beat, stronger patient growth, pipeline progress and planned trial savings.
Read original at benzingaStocks · News reference
Wedbush Maintains Neutral on NovoCure, Raises Price Target to $20
Wedbush analyst David Nierengarten maintains NovoCure (NASDAQ:NVCR) with a Neutral and raises the price target from $18 to $20.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 24, 2026, 12:51 PM
- Checked
- Jul 24, 2026, 12:51 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
HC Wainwright & Co. Maintains Buy on NovoCure, Raises Price Target to $52
HC Wainwright & Co. analyst Emily Bodnar maintains NovoCure (NASDAQ:NVCR) with a Buy and raises the price target from $46 to $52.
Read original at benzingaCrude Oil Rises Sharply; T-Mobile Shares Fall Following Q2 Results
US stocks lower, Dow down 0.92%, NASDAQ 2.03% decline. T-Mobile stock falls 5%. NVE Corp up 38%, Novocure up 25%, Cleveland-Cliffs up 19%
Read original at benzinga